Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Investing Activities (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Cash from Investing Activities for 5 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 110.12% year-over-year to -$2.0 million, compared with a TTM value of -$37.8 million through Dec 2025, down 106.94%, and an annual FY2025 reading of -$37.8 million, down 106.94% over the prior year.
  • Cash from Investing Activities was -$2.0 million for Q4 2025 at Aligos Therapeutics, down from $47.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $47.7 million in Q3 2025 and bottomed at -$88.6 million in Q1 2024.
  • Average Cash from Investing Activities over 5 years is -$1.7 million, with a median of $4.8 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 723.17% in 2022, then surged 285414.29% in 2024.
  • Year by year, Cash from Investing Activities stood at -$16.5 million in 2021, then surged by 170.42% to $11.6 million in 2022, then tumbled by 100.06% to -$7000.0 in 2023, then soared by 285414.29% to $20.0 million in 2024, then crashed by 110.12% to -$2.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ALGS at -$2.0 million in Q4 2025, $47.7 million in Q3 2025, and -$39.4 million in Q2 2025.